CN115702152A - 内磺酰胺衍生物及其应用 - Google Patents

内磺酰胺衍生物及其应用 Download PDF

Info

Publication number
CN115702152A
CN115702152A CN202180043987.3A CN202180043987A CN115702152A CN 115702152 A CN115702152 A CN 115702152A CN 202180043987 A CN202180043987 A CN 202180043987A CN 115702152 A CN115702152 A CN 115702152A
Authority
CN
China
Prior art keywords
compound
added
mol
ring
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043987.3A
Other languages
English (en)
Inventor
夏建华
贺海鹰
江志赶
张晓�
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN115702152A publication Critical patent/CN115702152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

本发明公开了一类内磺酰胺衍生物，以及在制备治疗相关疾病的药物中的应用。具体公开了式(III)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180043987.3A 2020-04-22 2021-04-21 内磺酰胺衍生物及其应用 Pending CN115702152A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010324017 2020-04-22
CN2020103240178 2020-04-22
CN202010406044X 2020-05-14
CN202010406044 2020-05-14
CN202011059012 2020-09-30
CN2020110590123 2020-09-30
PCT/CN2021/088736 WO2021213445A1 (zh) 2020-04-22 2021-04-21 内磺酰胺衍生物及其应用

Publications (1)

Publication Number Publication Date
CN115702152A true CN115702152A (zh) 2023-02-14

Family

ID=78270265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043987.3A Pending CN115702152A (zh) 2020-04-22 2021-04-21 内磺酰胺衍生物及其应用

Country Status (2)

Country Link
CN (1) CN115702152A (zh)
WO (1) WO2021213445A1 (zh)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015321B2 (en) * 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
SI3587420T1 (sl) * 2017-02-23 2021-09-30 Fujian Cosunter Pharmaceutical Co., Ltd. Triciklična spojina in njene uporabe
CA3055194A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
WO2019206072A1 (zh) * 2018-04-24 2019-10-31 浙江海正药业股份有限公司 磺酰胺芳基甲酰胺衍生物及其制备方法和用途
WO2020051320A1 (en) * 2018-09-05 2020-03-12 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
US20220081433A1 (en) * 2018-09-05 2022-03-17 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv

Also Published As

Publication number Publication date
WO2021213445A1 (zh) 2021-10-28

Similar Documents

Publication Publication Date Title
CN107207487B (zh) 用于提高cftr活性的化合物、组合物和方法
EP3538526B1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
CN104892582B (zh) 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
CN108283000A (zh) γ-羟基丁酸的前药及其组合物和用途
CN111247151B (zh) 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用
CN105440032B (zh) 作为enac阻断剂的吡嗪衍生物
CN108929263B (zh) 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途
CN107849017A (zh) 作为magl抑制剂的1,1,1‑三氟‑3‑羟基丙‑2‑基氨基甲酸酯衍生物及1,1,1‑三氟‑4‑羟基丁‑2‑基氨基甲酸酯衍生物
JP2020500207A (ja) カルパインモジュレーター及びそれらの治療上の使用
CN109996541A (zh) N-酰基氨基酸化合物及其使用方法
CN104837830B (zh) 作为cb2受体激动剂的吡嗪衍生物
WO2004064730A2 (en) Compounds, compositions and methods
JPS6393757A (ja) ジアミン化合物、その製造方法および該化合物を含有する鎮痛剤
JP7015092B2 (ja) ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
CN104603146B (zh) 环肽类化合物及其作为药物的用途
CN112312910A (zh) 人整合素α4β7拮抗剂
CN107011272A (zh) 吡嗪衍生物
CN112566907A (zh) 作为ret抑制剂的吡唑衍生物
TWI462919B (zh) 烷基－雜環之胺基甲酸酯衍生物，其製備及其治療用途
CN107646036A (zh) 可用作5‑脂氧合酶激活蛋白(flap)抑制剂的吡唑衍生物
CN114846009A (zh) 具有khk抑制作用的化合物
CA2092112A1 (en) Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use
CN114105950A (zh) 吡唑类化合物及其应用
CN114929694A (zh) 肾上腺素能受体adrac2拮抗剂
JPH02207070A (ja) アミノ酸イミド誘導体、それを含有する医薬及び該化合物の製造中間体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination